Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Other Events
Item 8.01.
| Other Events. |
On February 27, 2017, Titan Pharmaceuticals, Inc. (the Company)
announced that it has received a request from the U.S. Food Drug
Administration (the FDA) in a telephone communication for
additional information in connection with its review of the
Companys Investigation New Drug Application (IND) for it ProNeura
ropinirole implant. Initiation of the clinical trial is on hold
pending submission of the requested information and the FDAs
clearance of the IND.
A copy of the press release issued by the Company is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description |
| 99.1 | Press Release, dated February 27, 2017. |
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Recent Trading Information
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) closed its last trading session up +0.05 at 3.80 with 130,831 shares trading hands.
